CSTONE PHARMA-B (02616) announced that the company will present its autoimmune and inflammation pipeline candidate CS2015 (OX40L/TSLP bispecific antibody) at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in the form of an e-poster and live oral presentation. ACAAI is one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting experts and scholars worldwide to discuss the latest scientific advancements. This marks CS2015's first appearance at an international academic conference, with the full abstract and e-poster now officially available on the ACAAI website.

CS2015 features an asymmetric molecular structure, simultaneously targeting OX40L and TSLP—two key regulators of type 2 inflammation clinically validated for effective blockade. The molecule incorporates a mutated Fc to reduce binding with FcγR and extend its in vivo circulation half-life, ultimately optimizing pharmacokinetic (PK) properties to support long dosing intervals. CS2015's outstanding molecular stability ensures the feasibility of developing high-concentration subcutaneous formulations. Additionally, its excellent developability lays the foundation for high-yield and scalable production.